October 30, 2016 - Curasight

Skip to main content Skip to navigation Skip to search

About Us
Technology
Pipeline
- Programmes
News and media
Investor
Contact

Home
News and media
News
2016
October 30, 2016

Press releases
News
Curasight in the Media
Conferences
Subscribe

October 30, 2016

October 30, 2016

Our phase I study just published online in Journal of Nuclear Medicine

E-mail LinkedIn

Curasight is a pioneer in the field of exploiting a novel PET imaging target – the urokinase-type plasminogen activator receptor (uPAR) – for improved prostate cancer diagnose.

Subscribe

Subscribe to get the latest news first.

Choose type

Financial reports Press releases

E-mail

Something went wrong - please make sure you entered the correct email.

Thank you. You will get an e-mail message to activate your subscription.

News and media
Contact
Terms of use

Copyright 2021 © Curasight

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here